This listing of claims will replace all prior versions, and listings of claims in the application:

## **Listing of Claims:**

- 1. (Cancelled)
- 2. (Current Amended) A method of detecting a disorder involving defective binding of P-selectin glycoprotein ligand in a patient between leukocytes and activated platelets or endothelial cells, comprising:

providing an antibody to a protein component or to a carbohydrateprotein component of P-selectin glycoprotein ligand, the
glycoprotein ligand comprising a fucosylated sialylated glycoprotein
containing sialyl Lewis\* antigen and the glycoprotein ligand having
an apparent relative molecular weight of about 120,000 D as
assessed by SDS-PAGE under reducing conditions and wherein the
antibody has binding specific for P-selectin glycoprotein ligand and
wherein the antibody inhibits binding of P-selectin glycoprotein
ligand to P-selectin; and-

testing measuring the binding of the antibody to leukocytes obtained from the a patient to the antibody; and

determining that the leukocytes will have defective binding to activated

platelets or endothelial cells of the patient when the leukocytes are

not able to bind to the antibody.

3. (Cancelled)